Filing Details

Accession Number:
0001062993-11-004916
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-12-14 17:57:33
Reporting Period:
2011-12-12
Filing Date:
2011-12-14
Accepted Time:
2011-12-14 17:57:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1369868 China Biologic Products Inc. CBPO Biological Products, (No Disgnostic Substances) (2836) 752308816
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1302396 Tristan Yuyun Kuo No. 14 East Hushan Road
Tai'An City
Shandong F4 271000
Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-12 25,000 $4.00 25,000 No 4 M Direct
Common Stock Disposition 2011-12-12 25,000 $11.34 0 No 4 S Direct
Common Stock Acquisiton 2011-12-13 20,000 $4.00 20,000 No 4 M Direct
Common Stock Disposition 2011-12-13 20,000 $11.69 0 No 4 S Direct
Common Stock Acquisiton 2011-12-14 5,000 $4.00 5,000 No 4 M Direct
Common Stock Disposition 2011-12-14 5,000 $11.60 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-12-12 25,000 $0.00 25,000 $4.00
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-12-13 20,000 $0.00 20,000 $4.00
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2011-12-14 5,000 $0.00 5,000 $4.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
135,000 2008-06-01 2018-06-01 No 4 M Direct
115,000 2008-06-01 2018-06-01 No 4 M Direct
110,000 2008-06-01 2018-06-01 No 4 M Direct
Footnotes
  1. Reflects previously reported stock options to purchase an aggregate of 160,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's equity incentive plan.